Mauna Kea Technologies : Mauna Kea and J&J move up a gear
>Launch of a study in pneumology - Mauna Kea begins an important stage today with the announcement of the launch of a first in human study combining its Cellvizio platform (miniprobe and needle-based confocal laser endomicroscopy) and Auris Health’s (Johnson & Johnson group) Monarch robot for the diagnosis of lung nodules. This is therefore a major materialisation of the company’s development in the pneumology field, the next major therapeutic area targeted by Mauna K...Mauna Kea Technologies is a global medical device company based in France. Co. is focused on innovations in the field of endomicroscopy (microscopic imaging during endoscopy procedures). Co. is predominately active in the advent of optical biopsy. Co. researches, develops and markets innovative tools to visualize and detect cellular abnormalities during endoscopic procedures. Co.'s flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Co. has marketing authorizations in Thailand, United Kingdom, U.S., Brazil, Chile, South Korea, Poland, Russia and Saudi Arabia.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.